Literature DB >> 18765122

Bladder-preserving therapy for muscle-invasive bladder cancer: should it be recommended to appropriate patients?

Hideyuki Akaza1.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18765122     DOI： 10.1007/s11934-008-0044-x

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   3.092


× No keyword cloud information.
  12 in total

Review 1.  Radiotherapy and organ preservation in bladder cancer: are we ignoring the evidence?

Authors:  Mary Gospodarowicz
Journal:  J Clin Oncol       Date:  2002-07-15       Impact factor: 44.544

2.  The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan.

Authors:  Yoshiyuki Matsui; Hiroyuki Nishiyama; Jun Watanabe; Satoshi Teramukai; Yoshinari Ono; Shinichi Ohshima; Kiyohide Fujimoto; Yoshihiko Hirao; Masanori Fukushima; Osamu Ogawa
Journal:  Int J Clin Oncol       Date:  2005-04       Impact factor: 3.402

3.  A bladder preservation regimen using intra-arterial chemotherapy and radiotherapy for invasive bladder cancer: a prospective study.

Authors:  N Miyanaga; H Akaza; T Okumura; N Sekido; K Kawai; T Shimazui; K Kikuchi; K Uchida; H Takeshima; K Ohara; Y Akine; Y Ita
Journal:  Int J Urol       Date:  2000-02       Impact factor: 3.369

4.  Combined-modality treatment and organ preservation in bladder cancer. Do molecular markers predict outcome?

Authors:  Christian Weiss; Franz Rödel; Ina Wolf; Thomas Papadopoulos; Dirk G Engehausen; Karl M Schrott; Rolf Sauer; Claus Rödel
Journal:  Strahlenther Onkol       Date:  2005-04       Impact factor: 3.621

Review 5.  Combined intraarterial chemotherapy and radiotherapy in the treatment of bladder carcinoma.

Authors:  A Mokarim; M Uetani; N Hayashi; I Sakamoto; K Minami; Y Ogawa; M Ochi; Y Matsuoka; K Hayashi; K Nomata
Journal:  Cancer       Date:  1997-11-01       Impact factor: 6.860

6.  Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder.

Authors:  C N Sternberg; M G Arena; F Calabresi; P De Carli; A Platania; M Zeuli; D Giannarelli; A Cancrini; V Pansadoro
Journal:  Cancer       Date:  1993-09-15       Impact factor: 6.860

7.  Clinical outcome of a large-scale multi-institutional retrospective study for locally advanced bladder cancer: a survey including 1131 patients treated during 1990-2000 in Japan.

Authors:  Hiroyuki Nishiyama; Tomonori Habuchi; Jun Watanabe; Satoshi Teramukai; Harue Tada; Yoshinari Ono; Shinichi Ohshima; Kiyohide Fujimoto; Yoshihiko Hirao; Masanori Fukushima; Osamu Ogawa
Journal:  Eur Urol       Date:  2004-02       Impact factor: 20.096

8.  Effective bladder sparing therapy with intra-arterial cisplatin and radiotherapy for localized bladder cancer.

Authors:  Libni Eapen; David Stewart; John Collins; Rebecca Peterson
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

9.  Background Variables for the Patients with Invasive Bladder Cancer Suitable for Bladder-preserving Therapy.

Authors:  Naoto Miyanaga; Hideyuki Akaza; Shiro Hinotsu; Akira Joraku; Takehiro Oikawa; Noritoshi Sekido; Koji Kawai; Toru Shimazui
Journal:  Jpn J Clin Oncol       Date:  2007-10-26       Impact factor: 3.019

10.  Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results.

Authors:  Claus Rödel; Gerhard G Grabenbauer; Reinhard Kühn; Thomas Papadopoulos; Jürgen Dunst; Martin Meyer; Karl M Schrott; Rolf Sauer
Journal:  J Clin Oncol       Date:  2002-07-15       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.